Irisin Levels in Cerebrospinal Fluid Correlate with Biomarkers and Clinical Dementia Scores in Alzheimer Disease
- PMID: 38780366
- DOI: 10.1002/ana.26946
Irisin Levels in Cerebrospinal Fluid Correlate with Biomarkers and Clinical Dementia Scores in Alzheimer Disease
Abstract
Objective: Irisin, released by muscles during exercise, was recently identified as a neuroprotective factor in mouse models of Alzheimer disease (AD). In a cohort of AD patients, we studied cerebrospinal fluid (CSF) and plasma irisin levels, sex interactions, and correlations with disease biomarkers.
Methods: Correlations between CSF and plasma irisin levels and AD biomarkers (amyloid β 1-42, hyperphosphorylated tau, and total tau [t-tau]) and Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) were analyzed in a cohort of patients with Alzheimer dementia (n = 82), mild cognitive impairment (n = 44), and subjective memory complaint (n = 20) biologically characterized according to the recent amyloid/tau/neurodegeneration classification.
Results: CSF irisin was reduced in Alzheimer dementia patients (p < 0.0001), with lower levels in female patients. Moreover, CSF irisin correlated positively with Aβ42 in both female (r = 0.379, p < 0.001) and male (r = 0.262, p < 0.05) patients, and negatively with CDR-SOB (r = -0.234, p < 0.05) only in female patients. A negative trend was also observed between CSF irisin and t-tau levels in all patients (r = -0.144, p = 0.082) and in the female subgroup (r = -0.189, p = 0.084).
Interpretation: The results highlight the relationship between irisin and biomarkers of AD pathology, especially in females. Our findings also offer perspectives toward the use of irisin as a marker of the AD continuum. ANN NEUROL 2024;96:61-73.
© 2024 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
References
-
- Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease. Nat Rev Dis Primers 2021;7:33.
-
- Li X, Feng X, Sun X, et al. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019. Front Aging Neurosci 2022;14:937486.
-
- GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022;7:e105–e125.
-
- Logroscino G, Urso D, Savica R. Descriptive epidemiology of neurodegenerative diseases: what are the critical questions? Neuroepidemiology 2022;56:309–318.
-
- Self WK, Holtzman DM. Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med 2023;29:2187–2199.
MeSH terms
Substances
Grants and funding
- CUPB84I18000540002/Tecnopolo per la Medicina di Precisione, D.G.R. n. 2117 of 21.11.2018; Research Center of Excellence for Neurodegenerative Diseases and Brain Aging, University of Bari
- Research Center of Excellence for Neurodegenerative Diseases and Brain Aging, University of Bari
- CUP/National Recovery and Resilience Plan, Investment PE8-Project Age-It: "Ageing Well in an Ageing Society."
- B83C22004800006/National Recovery and Resilience Plan, Investment PE8-Project Age-It: "Ageing Well in an Ageing Society."
LinkOut - more resources
Full Text Sources
Medical